All In Biotech

Drug Trial Radar · NCT05132777

Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer

A Phase II, Open Label, Multi-center Study to Assess the Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

Last checked: Nov 19, 2026Latest source record: Nov 24, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

155

Planned (sponsor's estimate)

Start

Nov 20, 2021

Primary completion

Sep 30, 2023

Study completion Sep 30, 2024

Sponsor

Lead sponsor
Shanghai JMT-Bio Inc.Industry
Sponsor type
Industry
Collaborators
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
First posted
Nov 24, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a phase II, open label, multi-center study to evaluate the efficacy and safety of JMT101 combined with Osimertinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations.

Conditions

  • Locally Advanced or Metastatic Non-Small Cell Lung Cancer
  • EGFR Exon20 Insertion Mutations

Interventions

  • JMT101Drug

    JMT101, 6 mg/kg, IV infusion once every two weeks (one treatment cycle is 4 weeks).

  • Osimertinib Mesylate TabletsDrug

    Osimertinib, 160 mg, Oral administration once daily (one treatment cycle is 4 weeks).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Confirmed Objective Response Rate (ORR) Assessed by Blinded Independent Review Committee (IRC) per RECIST Version 1.1Time frame: From the first dose to disease progression or end of study, an average of 1 year

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.